Financials in USD. Standardized financial statements.
A compact view of how Supernus Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M | $520.40M | $392.75M | $408.90M | $302.24M | $215.00M |
| Revenue Growth? | +8.6% | +8.9% | -8.9% | +15.1% | +11.4% | +32.5% | -3.9% | +35.3% | +40.6% | 0.0% |
| Cost of Revenue? | $74.56M | $77.91M | $83.78M | $87.22M | $75.06M | $52.46M | $16.66M | $15.36M | $15.21M | $11.99M |
| Gross Profit? | $644.39M | $583.91M | $523.74M | $580.02M | $504.71M | $467.94M | $376.10M | $393.54M | $287.02M | $203.02M |
| Gross Margin? | +89.6% | +88.2% | +86.2% | +86.9% | +87.1% | +89.9% | +95.8% | +96.2% | +95.0% | +94.4% |
| Operating Expenses? | $681.25M | $502.25M | $529.01M | $533.89M | $418.69M | $294.24M | $227.52M | $249.10M | $187.48M | $148.80M |
| Operating Income? | -$36.86M | $81.67M | -$5.27M | $46.12M | $86.03M | $173.70M | $148.57M | $144.44M | $99.54M | $54.22M |
| EBITDA? | $42.53M | $178.28M | $90.04M | $153.36M | $129.19M | $210.54M | $180.42M | $151.51M | $107.67M | $56.62M |
| Income Before Tax | -$49.03M | $97.87M | $2.77M | $60.74M | $73.17M | $168.65M | $147.49M | $140.18M | $100.62M | $50.37M |
| Income Tax Expense | -$10.48M | $24.00M | $1.45M | $32,000 | $19.75M | $41.70M | $34.43M | $29.18M | $43.33M | -$40.85M |
| Net Income? | -$38.55M | $73.86M | $1.32M | $60.71M | $53.42M | $126.95M | $113.06M | $110.99M | $57.28M | $91.22M |
| EPS? | $-0.68 | $1.34 | $0.02 | $1.13 | $1.01 | $2.41 | $2.16 | $2.13 | $1.13 | $1.84 |
| Diluted EPS? | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality